VP, Research & Development and Global Head Biologics Safety, MedImmune
10th-11th Oct 2019
Registration from 8am
London, United Kingdom
London Heathrow Marriott Hotel
Immuno-oncology has already established itself as a vital weapon in the fight against cancer, and with a market value expected to reach $125 billion by 2024, it continues to revolutionize patient care.
The Research & Technology Series: Immuno-oncology is a multi-event forum for exploring the latest developments in key areas of immuno-oncology. It will bring together 350 industry and academic leaders at the cutting edge of research and provides you with an opportunity to make connections with industry experts, researchers, investors and businesses in your field.
100 individual presentations will be given across the five meetings. Talks will look to cover the potential of predictive biomarkers such as the tumour mutation burden to enhance personalised care, and new biomarker and antigen discovery, as well as the development of novel large molecule immunotherapies including new antibody formats and T cell therapeutics.
Biotechnologist and associate professor for molecular biology, University of Natural Resources and Applied Life Sciences
Head, Department of Drug Development and Innovation (D3i), Institut Curie, France
Professor of Chemistry, Deputy Director and Co-Founder of AIBN, University of Queensland, Australia
Professor of Radiation Oncology, Dana Farber Cancer Institute and Harvard Medical School, USA